Time magazine has called Dr. Robert Enright “the forgiveness trailblazer” because of his groundbreaking scientific discoveries related to how forgiveness favorably impacts both emotional and physical health. Now the doctor (a Ph.D., not a physcian) is working with medical specialists in Europe to discover if forgiveness can improve the health of patients with multiple myeloma–a cancer of cells in the immune system.
Dr. Enright will provide an update on his latest forgiveness challenge at the 17th Annual Fall Cancer Conference sponsored by the University of Wisconsin Carbone Cancer Center on Friday, Oct. 19, 2018, at the Monona Terrace in Madison, Wisconsin.
Advances in Multidisciplinary Cancer Care 2018 is the title of the day-long conference that will focus on “Unique Challenges Faced by Young Adults With Cancer.” Dr. Enright’s presentation begins at 2:00 pm and is entitled “Forgiveness as a Strengthening of Emotional Health in Cancer Patients and Their Families.”
While the conference is designed primarily for individuals who are involved in cancer treatment and education of cancer patients and their families, conference organizers are also encouraging patients, caregivers and community members to attend. For registration information, visit the 17th Annual Fall Cancer Conference website.
Forgiveness therapy for cancer patients is not a new endeavor for Dr. Enright. He and his colleagues completed a clinical trial nearly 10 years ago with cancer patients who were receiving end-of-life hospice care. That study found that as the patients’ physical health decreased, measures of emotional health increased if they completed forgiveness therapy.
Next, they completed a clinical trial with patients in cardiac units, where they observed a physical benefit to forgiveness: cardiac health measures, such as blood flow to the heart, increased in the patients on the intervention. Forgiveness therapy, then, has shown both palliative and physical benefits in medical settings.
“So now we’re working with physicians in Europe in regards to multiple myeloma,” Enright says. He explained that multiple myeloma is a cancer of cells in the immune system, that stress is known to compromise the immune system, and that forgiveness therapy has been demonstrated to reduce stress.
Interestingly, case studies in patients with low-grade multiple myeloma have already found disease stabilization if patients complete forgiveness therapy. Could forgiveness – a relatively inexpensive, non-drug-based intervention – become a part of some patients’ treatment plans? Enright and medical colleagues think the answer may be yes, and they are currently developing a clinical trial to understand if forgiveness improves myeloma patient health through measurable biological markers.
“That’s why next we need to do a clinical trial, for cause and effect,” Enright says. “The physicians will measure markers of immune system strength, and then I would bring the hope and anxiety scales to measure the psychological markers.”